CoChat

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Open access
Zhang, Tao, Qu, Rong, Chan, Shingpan, Lai, Mengzhen, Tong, Linjiang, Feng, Fang, Chen, Hongyu, Song, Tingting, Song, Peiran, Bai, Gang, Liu, Yingqiang, Wang, Yanan, Li, Yan, Su, Yi, Shen, Yanyan, Sun, Yiming, Chen, Yi, Geng, Meiyu, Ding, Ke, Ding, Jian, Xie, Hua · 2020 · Molecular Cancer
Cited by 141

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFRT 790 Mmutation. The discovery of third-generation EGFR inhibitors overcoming EGFRT 790 Mand their new resistance mechanisms have attracted much attention. Methods: We examined the antitumor activities and potential resistance mechanism of a novel EGFR third-generation inhibitor in vitro and in vivo using ELISA, SRB assay, immunoblotting, flow cytometric analysis, kinase array, qRT-PCR and tumor xenograft models. The clinical effect on a patient was evaluated by computed tomography scan. Results: We identified compound ASK120067 as a novel inhibitor of EGFRT 790 M, with selectivity over EGFRWT. ASK120067 exhibited potent anti-proliferation activity in tumor cells harboring EGFRT 790 M(NCI-H1975) and sensitizing mutations (PC-9 and HCC827) while showed moderate or weak inhibition in cells expressing EGFRWT. Oral administration of ASK120067 induced tumor regression in NSCLC xenograft models and in a PDX model harboring EGFRT 790 M. The treatment of one patient with advanced EGFR T790M-positive NSCLC was described as proof of principle. Moreover, we found that hyperphosphorylation of Ack1 and the subsequent activation of antiapoptotic signaling via the AKT pathway contributed to ASK120067 resistance. Concomitant targeting of EGFR and Ack1 effectively overrode the acquired resistance of ASK120067 both in vitro and in vivo. Conclusions: Our results idenfity ASK120067 as a promising third-generation EGFR inhibitor and reveal for the first time that Ack1 activation as a novel resistance mechanism to EGFR inhibitors that guide to potential combination strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-020-01202-9

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 141

Metadata

Authors
Zhang, T., Qu, R., Chan, S., Lai, M., Tong, L., Feng, F., Chen, H., Song, T., Song, P., Bai, G., Liu, Y., Wang, Y., Li, Y., Su, Y., Shen, Y., Sun, Y., Chen, Y., Geng, M., Ding, K., Ding, J., & Xie, H.
Venue
Molecular Cancer
Published
2020-05-13
Volume
19
Issue
1
Pages
102-102
ISSN
1476-4598 (ISSN-L)
OpenAlex
W3024740892
Cited by
141
References
14
FWCI
12.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. https://app.cochat.ai/papers/10.1186/s12943-020-01202-9
The paper
Zhang, T., Qu, R., Chan, S., Lai, M., Tong, L., Feng, F., Chen, H., Song, T., Song, P., Bai, G., Liu, Y., Wang, Y., Li, Y., Su, Y., Shen, Y., Sun, Y., Chen, Y., Geng, M., Ding, K., . . . Xie, H. (2020). Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Molecular Cancer. https://doi.org/10.1186/s12943-020-01202-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.